F
F2G
Discovers and develops novel drugs for the treatment of life-threatening fungal diseases
At a glance
- Founded
- 1998
- Headquarters
- Manchester, United Kingdom
- Sector
- Biotech & Life Sciences
- Power Law
- Thoroughbred$100M+ revenue
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
- KNK Nominees
- MCMerifin Capital
- AVAstellas Venture
- BABankInvest
Series B and later14 investors entered at this stage
Heartcore Capital- NFNovartis Venture Fund
- ACAisling Capital
Morningside- AFAMR Action Fund
- NHNovo Holdings
- FPForbion Capital Partners
- SMSectoral Asset Management
- IGIntermediate Capital Group
- TMThe University of Manchester
Sofinnova Partners- CGCowen Group
- ASAdvent Life Sciences
- BPBrace Pharma
Ownership
Estimated cap table from Dealroom's shareholder data — share of equity by holder. Stakes as last recorded by Dealroom (2026). Percentages are indicative.
Some investors are hidden on this public profile. See the full cap table on Dealroom →
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Patents
9 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about F2G on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See F2G on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.